Print

IAVI P002

A Phase I Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TBC-M4, an env, gag, tat-rev, and nef-RT MVA HIV vaccine and a Prime-Boost Regimen with ADVAX, an env, gag, nef-tat and pol DNA HIV vaccine and TBC-M4.

Trial Details:

I Completed
International AIDS Vaccine Initiative (IAVI) November 01, 2008
TBC-M4,ADVAX DNA Nef, Gag, Env, Tat, Pol C; Pox env, gag, tat-rev, and nef-RT C
ADVAX DNA
TBC-M4 Viral Vector - Pox
United Kingdom 32
http://www.iavi.org